Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

1.5%

4 terminated out of 262 trials

Success Rate

91.8%

+5.3% vs benchmark

Late-Stage Pipeline

11%

29 trials in Phase 3/4

Results Transparency

4%

2 of 45 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

193Total
Not Applicable (77)
Early P 1 (1)
P 1 (13)
P 2 (73)
P 3 (27)
P 4 (2)

Trial Status

Recruiting92
Unknown60
Completed45
Not Yet Recruiting37
Active Not Recruiting14
Withdrawn8

Trial Success Rate

91.8%

Benchmark: 86.5%

Based on 45 completed trials

Clinical Trials (262)

Showing 20 of 20 trials
NCT06076135Phase 2Completed

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

NCT07724548RecruitingPrimary

Comparison Between Virtual vs in Person on Treatment Follow-up Visits of Radiotherapy

NCT07583550Phase 2Not Yet Recruiting

Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer

NCT07699913Not Yet Recruiting

Quality of Life of Patients Who Have Undergone Bilateral Mastectomy

NCT07686640Phase 3Not Yet Recruiting

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

NCT07686796Phase 3Not Yet Recruiting

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

NCT05417516Phase 3Recruiting

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

NCT07665736Not Yet RecruitingPrimary

Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study

NCT07339488Phase 2Recruiting

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

NCT04228991Phase 3Active Not Recruiting

Hypofractionated LocoRegional Radiotherapy in Breast Cancer

NCT07646639Phase 2Recruiting

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

NCT07645950Not Yet Recruiting

Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy

NCT03535623Not ApplicableCompleted

RIPC During Free Flap With Preoperative Radiotherapy

NCT07631962Completed

Impact of Radiotherapy on Survival in Breast Cancer Patients

NCT05871307Not ApplicableActive Not Recruiting

Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases

NCT07373496RecruitingPrimary

Patient Position Monitoring System for Beam Gated Radiation Therapy of Malignancies of the Chest and Upper Abdomen

NCT03870919Not ApplicableActive Not Recruiting

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT07583719Not ApplicableNot Yet RecruitingPrimary

Effects of Moderate-intensity Interval Aerobic Exercise (MIIAE) on Inflammatory, Immune, Metabolic, Physical Fitness, and Quality of Life Parameters in Breast Cancer Patients Undergoing Radiotherapy.

NCT07113275Phase 3Recruiting

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

NCT06805396Phase 2Recruiting

Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial

Scroll to load more

Research Network

Activity Timeline